Aa
Phase I Study New Hep C Drug for Peg/RBV Nonresponders
Anyone interested in joining a study for the evaluation of a new drug....pls read details below:
Get tested for hepatitis C
--------------------------------------------------------------------------------
Otros Titulares
Som
--------------------------------------------------------------------------------
Otros Titulares
Som
thanks for the details, Ben. Someone gave us a preview on an 8/8 thread, I wonder if they got their 30 subjects by now? I think it was mentioned that they were looking for 30 individuals, or did I imagine that one?
Phase I Study New Hep C Drug for Peg/RBV Nonresponders
Peregrine Pharmaceuticals' anti-viral Phase 1 trial is designed to evaluate the safety of escalating doses of Tarvacin in patients with chronic Hepatitis C virus infection.
Below is a summary of the trial parameters:
Tarvacin is a monoclonal antibody designed for solid-tumor cancers.
http://www.tarvacin.com
Protocol Title:
A Phase I Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin™) in Patients Chronically Infected with Hepatitis C Virus (HCV) who are Non-responders or Relapsers after Treatment with Pegylated Interferon plus Ribavirin
Contact Information
Karen Roberts, MS 714.508.6035 ***@****
PHASE I STUDY SITE
Bach & Godofsky, MD, PA, Bradenton, Florida, 34205, United States; Recruiting
Mickey Mays, RNMS, ARNP 941-746-2711 Ext. 39
Eliot W Godofsky, MD, Principal Investigator
Phase: I
Indications: Chronic Hepatitis C virus (HCV) Infection
Objectives:
--Determine safety and tolerability
--Characterize blood pharmacokinetics and viral kinetics
--Define the maximum tolerated dose (MTD) and/or maximum effective dose (MED)
Selected Eligibility Criteria:
Inclusion
--Must be 18 years of age
--Chronic HCV infection based on medical history and detectable serum HCV RNA
--Failure to respond to or relapse after treatment with pegylated interferon plus ribavirin
Exclusion
--No prior exposure to any chimeric antibody
--No decompensated clinical liver disease or cirrhosis or other cause of liver disease such as alcoholic liver disease
--No uncontrolled intercurrent disease
--No requirement for chronic daily treatment with NSAIDs, anti-platelet drugs or steroids
--Must not be pregnant or nursing
--No prior thrombotic or hemorrhagic disorders
--------------------------------------------------------------------------------
_______________________________________________
NATAP nataphcv mailing list -- ***@****
Peregrine Pharmaceuticals' anti-viral Phase 1 trial is designed to evaluate the safety of escalating doses of Tarvacin in patients with chronic Hepatitis C virus infection.
Below is a summary of the trial parameters:
Tarvacin is a monoclonal antibody designed for solid-tumor cancers.
http://www.tarvacin.com
Protocol Title:
A Phase I Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin™) in Patients Chronically Infected with Hepatitis C Virus (HCV) who are Non-responders or Relapsers after Treatment with Pegylated Interferon plus Ribavirin
Contact Information
Karen Roberts, MS 714.508.6035 ***@****
PHASE I STUDY SITE
Bach & Godofsky, MD, PA, Bradenton, Florida, 34205, United States; Recruiting
Mickey Mays, RNMS, ARNP 941-746-2711 Ext. 39
Eliot W Godofsky, MD, Principal Investigator
Phase: I
Indications: Chronic Hepatitis C virus (HCV) Infection
Objectives:
--Determine safety and tolerability
--Characterize blood pharmacokinetics and viral kinetics
--Define the maximum tolerated dose (MTD) and/or maximum effective dose (MED)
Selected Eligibility Criteria:
Inclusion
--Must be 18 years of age
--Chronic HCV infection based on medical history and detectable serum HCV RNA
--Failure to respond to or relapse after treatment with pegylated interferon plus ribavirin
Exclusion
--No prior exposure to any chimeric antibody
--No decompensated clinical liver disease or cirrhosis or other cause of liver disease such as alcoholic liver disease
--No uncontrolled intercurrent disease
--No requirement for chronic daily treatment with NSAIDs, anti-platelet drugs or steroids
--Must not be pregnant or nursing
--No prior thrombotic or hemorrhagic disorders
--------------------------------------------------------------------------------
_______________________________________________
NATAP nataphcv mailing list -- ***@****
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
